Advanced Search
FENG Lan-ying, HUANG Wen-ye. Expression and regulation of Bim protein in chronic myelogenous leukemia[J]. Journal of China Pharmaceutical University, 2009, 40(6): 571-575.
Citation: FENG Lan-ying, HUANG Wen-ye. Expression and regulation of Bim protein in chronic myelogenous leukemia[J]. Journal of China Pharmaceutical University, 2009, 40(6): 571-575.

Expression and regulation of Bim protein in chronic myelogenous leukemia

More Information
  • Aim :To investigate the expression and the regulation of Bim protein in leukemic cell of patient with chronic myelognous leukemia(CML). Methods :The primary leukemic cells from the peripheral blood or bone marrow of patients with CML were isolated and cultured.The expression of Bim in the present or absence of imatinib(BCR/ABL inhibitor) was detected by the Western blotting,immunohistochemical analysis and real-time quantitative PCR. Results :Bim was consecutively expressed in normal bone marrow,but significantly decreased in the bone marrow of patients with CML(P<0.05).Imatinib significantly enhanced Bim mRNA transcription and expression in the manner of time- and dose-dependence.Moreover,there was reverse correlation between Bim protein level and the percent of leukemic cell in bone marrow(r=0.849 1,P<0.05). Conclusion :Bim is the Bcl-2 family pro-apoptitic factor.The decreased expression of Bim could be vital in the CML,Bim protein up-expression following the suppression of BCR/ABL might be of importance in investigation of the Bim-induced apoptosis for potential clinical therapy.
  • Related Articles

    [1]LI Yin, GU Hongfeng, ZOU Yi, WANG Shuping, XU Yungen. Research progress of mono-(ADP-ribosyl) transferase family and their inhibitors in tumor therapy[J]. Journal of China Pharmaceutical University, 2021, 52(6): 643-652. DOI: 10.11665/j.issn.1000-5048.20210601
    [2]LI Fang, XIN Junbo, SHI Qin, MAO Chengqiong. Advances in near infrared photoimmunotherapy of tumor[J]. Journal of China Pharmaceutical University, 2020, 51(6): 664-674. DOI: 10.11665/j.issn.1000-5048.20200604
    [3]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [4]TANG Keqin, LIN Huaqing, LI Shuhong, DONG Lixin, LU Bohong, JIANG Hong. Advances in tumor targeted nanocrystals[J]. Journal of China Pharmaceutical University, 2020, 51(4): 418-424. DOI: 10.11665/j.issn.1000-5048.20200405
    [5]CHEN Ye, YIN Jun, YAO Wenbing, GAO Xiangdong. Advances of DNA-based nanomaterials in tumor therapy[J]. Journal of China Pharmaceutical University, 2020, 51(4): 406-417. DOI: 10.11665/j.issn.1000-5048.20200404
    [6]GUO Yahui, LU Peng, WANG Yubin, ZHANG Huibin. Progress in the researches for antitumor NEDD8 activating enzyme inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 646-653. DOI: 10.11665/j.issn.1000-5048.20170603
    [7]LIU Zongliang, ZHANG Renmei, MENG Qingguo. Advances of targeting heat shock protein 70 drugs[J]. Journal of China Pharmaceutical University, 2017, 48(4): 416-424. DOI: 10.11665/j.issn.1000-5048.20170405
    [8]LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
    [9]LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
    [10]DENG Lian-bai, LI Ai-xiu, JIN Yu-rui. Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target[J]. Journal of China Pharmaceutical University, 2011, 42(6): 578-584.

Catalog

    Article views (1078) PDF downloads (1475) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return